This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Confirm it is not Walters - it is posted on his sites discusion forum, but the source was the same - moneym4ker - 24 Nov'05 - 09:31 - 6657 of 6660 on ADVFN. The implication is that it is David Best but I have no idea of its authenticity.

Looks good to me I'm in long term anyway. EK needs to keep his finger on the pulse with this one, he's still short. Rather him that me.

MS

David Best, interesting.

cheers GF.

GF

Could be a wind up/ramp, but does look and read real enough.

MS

It has to be DB...or someone pretending to be him .

why post this way if it's DB-surely he would make an official announcement.

The post has been removed from ADVFN Board for what reason i`m not sure ?
if it was because it was a ramp some people on these BB`s are going to be very busy pulling posts on a lot of other threads!
DB66

Clearly written by a top level director to an analyst contact.

very quiet in this thread, you guys left for holiday? hello... :-P

anyone got any news? say if MMG would go up to 190p by end of this year?

Hi swseun ,yes it is quiet on this thread at the moment and i have got to say i`m a little bit disappointed with the share price at the moment.I really did think it would be ticking up to the 1.60 by now given that we should be close to news about trials being released.
DB66

post 1950 is a piece by David Best, I received a copy with his e-mail address still showing in the forwarded section.

Erik the Red

Well thats good news. Might be better DB if news comes out when nobodys expecting it on a good day on the market. Could really shoot up onto the leader board. Finding markets in general very dull at the moment.

cheers GF.

GF, there are more leaks in this company than a rusty bucket, by the time the news arrives the price will have already shot up.

Erik the Red

from advfn.

BennytheBall - 29 Nov'05 - 20:03 - 6683 of 6685


http://www.platinum.matthey.com/media_room/1133262002.html

SAFC announces ruthenium cancer therapy agreement - 29th November 2005

Sigma-Aldrich Fine Chemicals (SAFC) has announced that its pharmaceutical branch has been appointed to deliver current good manufacturing practices (cGMF) of its lead ruthenium cancer therapy compounds.

Speaking at the CPhI Expo in Madrid, SAFC revealed that the wholly-owned cancer therapy subsidiary of the Medical Marketing International (MMI) Group, OncoSense, has chosen SAFC for the manufacturing and distribution of the ruthenium cancer therapy.

Mark Burton, technical manager of MMI, explained to in-Pharma Technologist: "Under the terms of the agreement, OncoSense will retain ownership of all existing and any new intellectual property that arises out of the manufacturing process."

The deal will provide a major platform for the ruthenium cancer therapy and the manufacturing of the new product will begin in the US.

Manufacturing the new therapy in the US is part of an effort to increase awareness in the country, which is considered to have potentially the largest market for the product.

Ruthenium is becoming an increasingly important element in the treatment of illnesses such as cancer, as highlighted by a recent ?0 million investment in the MMI to develop its research and manufacturing programmes, including those involving ruthenium.

yup db66, I am a bit disappointed as well, hopfully it will be up soon and all the MMI buyers would have a "profitable" X'mas. btw, the trading of MMI is a bit weak as well, isn't it? even buyer back after the news out, the market price hasn't been pushed up a lot compare to its fall. any comment?

AGM Highlights:

Genvax

Approval to commence colon cancer clinical trial
Final lymphoma trial results expected December 2005 ???
Myeloma and prostate cancer trials ongoing
DNA vaccine clinical trial for CMV (cytomegolovirus) ongoing
DNA vaccine for influenza in development
DNA vaccine for undisclosed bacterial infection in development.
DNA vaccines for pandemics - partner discussions ongoing

No sign of results yet or buying to indicate they are on there way.
Could they be delayed?

db66

huh... it is pain to wait, are we getting genvax results this month?

Results were no surprise but were accompanied by the very upbeat statement below from David Best.


Summary and outlook

The first half of the financial year has shown significant and positive
developments across our portfolio of potential blockbuster therapies for major
areas of unmet need in cancer and infection. These developments, together with a
strong balance sheet and a stronger team mean that MMI is ideally placed as it
enters the commercial stages of its development. Just one commercial agreement
with a major pharmaceutical company for one of MMI's products could transform
the business and its value.

David Best
EXECUTIVE CHAIRMAN
15 December 2005

DB66

Same as 2004, raised money, sp up and down at around the placement price whilst we wait for news. Progress made in 2005, nice profits for me having bought at sub 70p several times and sold at 185p and 271p. Back in at 122p and waiting for 2006 which should be even better for MMG and its shareholders.